Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Individualized Treatment for Relapsed/Refractory Multiple Myeloma Based on High Throughput Drug Sensitivity and Genomics Data

NCT03389347 is registered in ClinicalTrials.gov with University of Washington as lead sponsor.

NCT NCT03389347
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03389347 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Individualized Treatment for Relapsed/Refractory Multiple Myeloma Based on High Throughput Drug Sensitivity and Genomics Data
Lead sponsor
University of Washington
Phase
Not applicable
Overall status
Completed
Start date
February 14, 2018
Completion date
July 24, 2026
Enrollment
40 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

plasma cell leukemia, recurrent multiple myeloma, refractory multiple myeloma